What Akoya Biosciences does

Akoya Biosciences is a spatial biology company that designs and commercializes high-plex multiplexed tissue imaging platforms for single-cell resolution protein and RNA analysis in intact tissue samples. The company's product portfolio centers on the PhenoCycler-Fusion and PhenoImager (HT and Fusion) instruments, supported by proprietary PhenoCode Discovery Panels spanning immune-oncology, neurobiology, mouse immuno-oncology, mouse neurobiology, and metabolism, as well as PhenoCode Signature Panels and the PhenoCode Molecular Barcoding Kit. Analysis is enabled through the Spatial Software Suite (phenoptr, phenoptrReports, inForm, and Phenochart), which provides automated tissue analysis, spatial relationship quantification, and visualization for multimarker studies. Akoya generates revenue through instrument sales and a recurring consumables stream (assay kits, panels, and reagents) sold directly to pharmaceutical and biotechnology researchers, academic and research institutions, and contract research organizations via direct sales and international distributors.

Following its July 2025 acquisition by Quanterix Corporation for approximately $286 million, Akoya's spatial tissue analysis capabilities have been integrated with Quanterix's Simoa ultra-sensitive liquid biomarker detection platform. The combined entity offers matched biomarker insights across blood, CSF, and tissue matrices for neurology, oncology, immunology, and cardiology applications, supported by the Accelerator Laboratory service offerings and clinical diagnostics (LucentAD Complete for Alzheimer's, Simoa NfL LDT). The integration has expanded the combined company's addressable market from $1 billion to $5 billion and resulted in continued product launches through May 2026, including the Content Innovation Engine, IO60 Spike-In Module, PhenoCode Molecular Barcoding Kit, and ADC Lung Cancer Panels.

Name

Akoya Biosciences

Legal name

Akoya Biosciences, Inc.

Website

https://akoyabio.com

Company type

Private

Founded year

2015

Operating status

Acquired

Headcount range

101–250 employees

Short description

Akoya Biosciences is a spatial biology company developing high-plex multiplexed tissue imaging instruments, assay panels, and software for single-cell resolution proteomic analysis, serving pharmaceutical, biotechnology, academic, and CRO researchers. Now integrated with Quanterix's Simoa liquid biomarker platform post-July 2025 acquisition.

Ownership category

akta.pro rank

Product category

Spatial Biology Instruments and Assays

NAICS

Analytical Laboratory Instrument Manufacturing (334516), Scientific Research and Development Services (5417)

SIC

Laboratory Analytical Instruments (3826), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling) (HLAAAIAF)

akta.pro secondary industries

Translational & Pharmacodynamic Biomarkers (MOA, target engagement, PD/PK-linked markers) (HLAAAMAD), In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy) (HLAAAIAK)

Keywords

• Spatial biology platforms
• Multiplex tissue imaging
• Spatial proteomics instruments
• Biomarker discovery assays
• Immuno-oncology research

Headquarters

HQ city

Marlborough

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations

Distribution channels2 records

Marketing channels4 records

Core offering

Akoya Biosciences develops and sells spatial biology instruments, assay panels, and software for high-plex tissue analysis at single-cell resolution. Its portfolio includes the PhenoCycler-Fusion and PhenoImager instrument families, PhenoCode Discovery and Signature assay panels covering immuno-oncology and neurobiology, and analysis software (phenoptr, inForm, Phenochart). Products support biomarker discovery, translational research, and clinical development workflows in pharma, biotech, and academic settings.

Product overview

Akoya Biosciences operates as a spatial biology and ultrasensitive biomarker technology company, now integrated into Quanterix Corporation following the July 2025 acquisition. The company offers a dual-modality platform combining spatial tissue analysis with Simoa liquid biomarker detection. The spatial biology portfolio centers on PhenoImager HT 2.0, PhenoCycler-Fusion 2.0, and PhenoImager Fusion instruments, supported by PhenoCode Discovery Panels (IO60, Neurobiology, Metabolism, Immuno-Oncology for human and mouse), PhenoCode Signature Panels, and PhenoCode Molecular Barcoding Kits for multiplexed tissue imaging. Analysis is enabled through phenoptr/phenoptrReports, inForm, and Phenochart software. The Simoa portfolio includes HD-X Analyzer, SR-X Biomarker Detection System, and SP-X Imaging and Analysis System, along with assay kits, reagents, and custom assay development services. Clinical diagnostics are offered through Lucent Diagnostics (LucentAD Complete for Alzheimer's, Simoa NfL LDT). Research services are provided via the Accelerator Laboratory. The combined platform delivers matched biomarker insights across blood, CSF, and tissue for neurology, oncology, immunology, and cardiology applications.

Differentiator

Problem solved

Functional benefit

Products and services

• PhenoImager HT 2.0 High-plex spatial proteomics instrument enabling high-throughput imaging of tissue samples at single-cell resolution for translational research and clinical workflows.
• Akoya PhenoCycler-Fusion 2.0 Automated spatial biology platform for high-plex protein and RNA detection in intact tissue samples, enabling comprehensive mapping of cell populations and interactions.
• Akoya PhenoImager Fusion Spatial imaging platform combining high-plex proteomics and transcriptomics capabilities for comprehensive tissue analysis in research applications.
• Human IO60 Protein PhenoCode Discovery Panel High-plex spatial proteomics panel measuring 60+ proteins simultaneously for comprehensive immune-oncology and immunology research applications.
• Human Neurobiology PhenoCode Discovery Panel Specialized spatial proteomics panel targeting 60+ proteins for neuroscience and neurodegeneration research, enabling detailed brain tissue analysis.
• Human Metabolism Spike-In Module Spike-in module extending the IO60 panel for metabolism research, enabling detection of metabolic pathway markers in tissue samples.
• Mouse Immuno-Oncology PhenoCode Discovery Panel Pre-configured spatial proteomics panel optimized for mouse models in immuno-oncology research, measuring key immune checkpoint and tumor microenvironment markers.
• Mouse Neurobiology PhenoCode Discovery Panel Spatial proteomics panel designed for mouse neurobiology research, enabling detailed analysis of neural cell populations and disease models.
• PhenoCode Signature Panels Curated collections of spatial biomarker panels targeting specific disease indications or research applications.
• PhenoCode Molecular Barcoding Kit Molecular barcoding kit with expanded chemistry for enhanced spatial multiplexing and detection sensitivity in tissue samples.
• ADC Lung Cancer Panels Specialized spatial biology panels for antibody-drug conjugate (ADC) research in lung cancer, enabling analysis of target expression and tumor microenvironment.
• phenoptr and phenoptrReports Software suite for spatial relationship analysis, enabling researchers to quantify and visualize cell-cell interactions and spatial patterns in tissue imaging data.
• inForm Automated tissue analysis software for multimarker studies, enabling consistent and reproducible extraction of quantitative data from spatial imaging experiments.
• Phenochart Visualization and annotation tool for spatial images, enabling researchers to view, navigate, and annotate high-plex tissue imaging data.
• Quanterix Spatial Accelerator Specialized service offering utilizing Akoya spatial biology technologies for tissue-based biomarker analysis through the Accelerator Laboratory.

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• 10x Genomics: 10x Genomics is a direct competitor in spatial biology, offering the Visium (transcriptomics) and Xenium (in situ single-cell imaging) platforms that overlap with Akoya's PhenoImager and PhenoCycler-Fusion instruments in pharma, biotech, and academic research accounts.
• NanoString Technologies (Bruker Spatial Biology): NanoString's GeoMx Digital Spatial Profiler and CosMx Spatial Molecular Imager directly compete with Akoya's high-plex spatial proteomics platforms for tissue-based biomarker discovery; NanoString's spatial biology assets are now owned by Bruker following its 2024 acquisition.
• Standard BioTools (formerly Fluidigm): Standard BioTools offers the Hyperion Imaging System (imaging mass cytometry) for high-plex spatial tissue analysis, addressing the same pharma translational research and immuno-oncology workflows as Akoya's PhenoImager platform.

Broad incumbents

• Bruker Corporation: Bruker is a broad life science and analytical instruments incumbent that acquired NanoString's spatial biology business, giving it a directly comparable product portfolio (CosMx, GeoMx) and substantial commercial reach across pharma and academic accounts that also buy Akoya systems.
• Cytiva (Danaher): Cytiva is a broad life sciences tools incumbent (part of Danaher) supplying instruments, reagents, and services to pharma and academic labs, including in situ hybridization and spatial workflow products that overlap with Akoya's installed-base channels and customer budgets.
• Bio-Techne: Bio-Techne is a diversified life-science research tools provider (proteomics reagents, antibodies, spatial/ExoDx offerings) that sells into the same pharma and academic spatial-biology buyers as Akoya, and has been expanding its spatial tissue analysis and antibody portfolio.
• Revvity (formerly PerkinElmer Life Sciences): Revvity supplies lab instruments, imaging reagents, and clinical/diagnostic tools used in pharma and academic translational research, competing for spatial biology and translational biomarker budget similar to what Akoya serves.

Emerging players

• Lunit: Lunit is an AI-driven medical image analysis company focused on spatial biomarkers in pathology (e.g., Lunit SCOPE IO for immuno-oncology), selling AI tissue-analysis software into pharma trials and clinical diagnostics contexts that also purchase Akoya spatial biology platforms.
• Biognosys: Biognosys is a proteomics CRO using mass spectrometry-based discovery and targeted proteomics (including its TrueDiscovery and TrueTarget platforms) for biomarker work that competes for translational pharma research budgets alongside Akoya's spatial proteomics offerings.

Others

• Indica Labs: Indica Labs provides HALO image analysis software and AI-powered spatial biology quantification tools used alongside spatial tissue imaging instruments (including Akoya's) in pharma and pathology workflows, making it a complementary/adjacent technology partner rather than a direct platform competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/AkoyaBio

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds4 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Akoya Biosciences